Biochanin A, Dimethyl Ether

Biochanin A, Dimethyl Ether

SCHEMBL5795557

COc1ccc(-c2coc3cc(OC)cc(OC)c3c2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
KDM4E B2RXH2 5/20 1.00
ALDH1A1 P00352 5/20 1.00
HSD17B10 Q99714 4/20 1.00
RAB9A P51151 4/20 1.00
NPC1 O15118 3/20 1.00
SMN1; SMN2 Q16637 5/20 0.82
TP53 P04637 3/20 0.82
MAPT P10636 3/20 0.82
HPGD P15428 2/20 0.82
THRB P10828 1/20 0.82
MEN1 O00255 3/20 0.74
KMT2A Q03164 3/20 0.74
CYP2D6 P10635 2/20 0.74
CYP2C9 P11712 2/20 0.74
NFKB1 P19838 2/20 0.74
CYP2C19 P33261 2/20 0.74
NFKB2 Q00653 2/20 0.74
RELA Q04206 2/20 0.74
CYP1A2 P05177 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28788159 0.91 KDM4E (0.83) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
5,7-Dimethoxyisoflavone SCHEMBL1675985 0.90 ALDH1A1 (1.00) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL30288208 0.89 CYP3A4 (0.81) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL13640733 0.89 CYP3A4 (0.81) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL1743412 0.88 ALDH1A1 (0.79) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL26145339 0.88 KDM4E (0.85) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL5624288 0.88 CYP3A4 (0.79) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL7056427 0.86 CYP3A4 (0.76) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL5623038 0.86 CYP3A4 (0.76) CYP3A4KDM4EALDH1A1HSD17B10RAB9A
SCHEMBL16335756 0.86 CYP3A4 (0.75) CYP3A4KDM4EALDH1A1HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES UNIVERSITÄT REGENSBURG (AT) 2023-05-18 US disclosed
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES UNIVERSITÄT REGENSBURG (AT) 2023-05-18 US disclosed
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-8481760-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2013-07-09 US disclosed
US-8481760-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2013-07-09 US disclosed
US-20120283313-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2012-11-08 US disclosed
WO-2010042933-A9 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-07-08 WO disclosed
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-06-03 US disclosed
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-06-03 US disclosed
WO-2010042933-A2 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-04-15 WO disclosed
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-05-14 US disclosed
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-05-14 US disclosed
WO-2009049214-A2 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-04-16 WO disclosed
WO-2006030322-A2 USE OF FLA VONE/FLA VANONE DERIVATIVES FN THE TREATMENT OR PREVENTION OF RESPIRATORY CONDITIONS UNIVERSITY OF MANITOBA (CA) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES SORBS1, SLC5A6, SLC20A1 CYP3A4 4678/4885KDM4E 2594/4885ALDH1A1 928/4885
US-20120283313-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.